Jay Chhablani

2 weeks ago | ophthalmologytimes.com | Jay Chhablani |Sydney M Crago

Jay Chhablani, MD, from the University of Pittsburgh Medical Center's Vision Institute discusses 3D choroidal vessel segmentation technology. Using advanced Plex elite Zeiss swept-source OCT imaging, his team has created a new tool to visualize and analyze Haller vessels in 3 dimensions – overcoming previous limitations of 2D imaging. Note: The following conversation has been lightly edited for clarity. Ophthalmology Times:Can you speak to the development of this 3-dimensional imaging?

3 weeks ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses a preliminary study of combination gene therapy targeting neovascular age-related macular degeneration. The therapy, a combination of AIBP, apoA-I and aflibercept, showed promise in a mouse study presented at the ARVO meeting, Chhablani said.

3 weeks ago | modernretina.com | Jay Chhablani |Sydney M Crago

Jay Chhablani, MD, from the University of Pittsburgh Medical Center's Vision Institute discusses 3D choroidal vessel segmentation technology. Using advanced Plex elite Zeiss swept-source OCT imaging, his team has created a new tool to visualize and analyze Haller vessels in 3 dimensions – overcoming previous limitations of 2D imaging. "We have been focused on choroid for more than a decade.

3 weeks ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses preliminary data from the ArMaDa study of OCU410 gene therapy for geographic atrophy presented at the ARVO meeting. In this phase 1/2 open-label dose-escalation trial, nine patients received a subretinal injection of low-dose, medium-dose or high-dose OCU410 (Ocugen), which delivers the RORA gene.

4 weeks ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses 24-month findings from the SAGA trial evaluating oral gildeuretinol for geographic atrophy. Daily 14 mg gildeuretinol (Alkeus Pharmaceuticals) was associated with a reduction in GA lesion growth, with greater reductions occurring between months 6 and 24, Chhablani said. Patients also had less visual acuity loss and improved quality of life scores, he said.